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AbstrACt
Introduction Several institutions and quality national 
agencies have fostered the creation of recommendations 
on what not to do to reduce overuse in clinical practice. 
In primary care, their impact has hardly been studied. The 
frequency of adverse events (AEs) associated with doing 
what must not be done has not been analysed, either. The 
aim of this study is to measure the frequency of overuse 
and AEs associated with doing what must not be done 
(commission errors) in primary care and their cost.
Methods and analysis A coordinated, multicentric, 
national project. A retrospective cohort study using 
computerised databases of primary care medical records 
from national agencies and regional health services will be 
conducted to analyse the frequency of the overuse due to 
ignore the do-not-do recommendations, and immediately 
afterwards, depending on their frequency, a representative 
random sample of medical records will be reviewed with 
algorithms (triggers) that determine the frequency of 
AEs associated with these recommendations. Cost will 
determine by summation of the direct costs due to the 
consultation, pharmacy, laboratory and imaging activities 
according to the cases.
Ethics and dissemination The study protocol has 
been approved by the Ethics Committee of Primary 
Care Research of the Valencian Community. We aim to 
disseminate the findings through international peer-
reviewed journals and on the website (http://www. nohacer. 
es/). Outcomes will be used to incorporate algorithms into 
the electronic history to assist in making clinical decisions.
trial registration number NCT03482232; Pre-results.
IntroduCtIon
Overdiagnosis, overuse, overmedicalisation 
and low-value care are terms that are being 
used to represent the provision of medical 
services for which the potential for harm 
exceeds the potential for benefit.1 This overuse 
of diagnostic and therapeutic resources poses 
problems for the health of individuals and 
for health systems everywhere.2–4 No medical 
specialty, not even primary care,5–7 is immune 
from this overuse. According to the sources 
of information used (claims by patients; clin-
ical histories; and surveys with professionals, 
patients and health managers), the extra 
costs from such overuse vary between 10% 
and 30% of the total health expenditures in 
highly developed countries.8 9 
The immediate causes of this overuse 
include10–14 insufficient updating of knowl-
edge by professionals, decisions based on 
the fear of facing future litigation (defensive 
medicine), the custom of continuing to do 
things that they have been doing until now, 
lack of time during consultation, inadequate 
incentives, influence by the pharmaceutical 
industry, inadequate communication with 
patients and pressure from patients who 
request diagnostic tests or treatments based 
on inadequate sources of information such as 
the internet.
do-not-do recommendations
Sometimes, the determination of overuse 
is simple, but in several services, the cases 
strengths and limitations of this study
 ► This is an overuse study conducted in  the prima-
ry care setting in a country with a national health 
system.
 ► This study develops a methodology for measuring 
the harm caused by ineffective practices.
 ► We use data from real clinical encounters.
 ► This approach identifies a part of the overuse related 
to safety and sustainability; however, the do-not-do 
recommendations (DNDs) may not always be appro-
priate for all cases of overuse.
 ► The magnitude of harm dues to overuse by ignoring 
DNDs could vary from mild to serious, introducing a 
detection bias.
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of overused are not clear. In recent years, the so-called 
‘Less is More Medicine’ movement has spread owing 
to the actions of institutions and scientific societies.15 16 
This movement has sought to identify ‘what must not 
be done’17 and it has led to informative and educational 
campaigns, including, for example, the ‘Choosing Wisely’ 
campaign,8 18 which is intended to raise awareness about 
the need to reduce requests for tests or for carrying out 
medical procedures thought to be unnecessary.
In 2007, the National Institute for Health and Care 
Excellence (NICE) created a database of a series of 
recommendations on relatively frequent practices 
that are considered inadequate based on sufficient 
evidence. These recommendations then became part of a 
‘do-not-do’ list. Currently, NICE19 lists about 850 practices 
with scientific evidence about their low effectiveness. In 
2009, the American Board of Internal Medicine organ-
ised the ‘Choosing Wisely’ campaign,18 which focused 
on avoiding the inappropriate use of diagnostic and 
therapeutic resources, directed towards both clinicians 
and patients. Its recommendations included 70 practices 
chosen from about 400 practices that were not shown to 
benefit certain profiles of patients. The ‘Do No Harm 
Project’ in Colorado (USA),20 ‘Slow Medicine’ in Italy,21 
‘Smarter Medicine’ in Switzerland22 and ‘Commitment 
to Quality by Scientific Societies’ by the Spanish Ministry 
of Health in collaboration with 39 scientific societies23 
are other examples of this commitment to attain better 
healthcare, intending to banish practices with poor or 
doubtful effectiveness.
Since 2010, the Archives of Internal Medicine journal 
(renamed JAMA Internal Medicine in 2013) of the Amer-
ican Medical Association has been publishing research 
under the title ‘Less is More’.24 This section of the 
journal includes studies on practices that either provide 
no benefits to patients or entail elevated risks without 
any offsetting sufficient benefit, with the goal of eradi-
cating such practices. The British Medical Journal heads 
the ‘Too Much Medicine’25 campaign with the goal of 
drawing attention to problems caused by overdiag-
nosing and wasting health resources. Lancet edits the 
series called ‘Right Care’,26 which includes studies on 
the frequency, causes, consequences and measures for 
reducing overuse.
Up to now, the results from these campaigns have hardly 
been conclusive. In the USA, 3 years after publication of 
the do-not-do recommendations (DNDs), Rosenberg et 
al9 found that the frequency of imaging for headaches 
and imaging techniques in cardiology had decreased, 
but that the use of nonsteroidal anti-inflammatories 
in patients with hypertension, heart failure or chronic 
kidney disease, in addition to the human papillomavirus 
test in women below 30 years of age, had increased. The 
usage frequency for antibiotics for sinusitis, as well as that 
for taking X-rays for low back pain and prior to chest 
surgeries, remained stable. Those authors concluded that 
greater efforts were necessary to achieve more widespread 
implementation of these recommendations given that, 
however successful that they were, hardly any change had 
been achieved.
When doing what must not be done causes harm
Overuse is related with low-value care, and the worst thing 
about it lies in obtaining a negative result when something 
that should not be done is done. One example of this is 
prescribing an unnecessary test or procedure included 
on the DNDs, which causes the patient harm (adverse 
event, AE). Although the frequency of doing what must 
not be done has been analysed in some studies outside 
Europe,3 5 6 12 14 the occurrence of AEs related with this 
overuse has not been studied systematically until now.
overuse in primary care
In the context of primary care, overuse has been studied 
much less. In 2011, the National Physicians Alliance 
carried out the ‘Promoting Good Stewardship in Clinical 
Practice’27 project, whose objective was to identify a list 
of top-5 practices that it would recommend to be elimi-
nated. In Spain in 2014, the Spanish Society of Family and 
Community Medicine produced, by consensus, an initial 
list of 15 DNDs in daily clinical practice, 10 of which 
were related to treatments and five to diagnostic tests.28 
The Spanish Paediatric Association prepared five DNDs 
with applications in primary care.29 Despite these efforts, 
however, the frequency with which these practices consid-
ered inappropriate persist in primary care clinics has 
not been determined. Furthermore, neither have their 
economic consequences nor the harm caused to patients 
have been examined.
study objectives
Primary objective
To estimate the frequency of AEs directly related with 
diagnostic and/or therapeutic indications to the patient 
for which consensus exists based on scientific evidence or 
agreement among experts (DNDs for primary care) that 
they should not have been indicated (commission errors) 
and their cost.
Secondary objectives
To measure the frequency of overuse and determine the 
extra costs incurred by indicating diagnostic tests and 
procedures and/or therapeutic included in the DNDs for 
primary care.
MEthods And AnAlysIs
This coordinated, multicentric and national research 
project is being conducted in the primary care setting in 
Spain in collaboration with investigators from Andalusia, 
Aragón, Castilla La Mancha, Catalonia, Valencian Commu-
nity, Madrid, Murcia, Navarre and the Basque Country. 
The research includes the steps outlined in figure 1. This 
project was approved by the National Research Agency 
in Spain, in November 2016. The research team started 
work in March 2017 and aim to complete it by December 
2019.
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A retrospective cohort study, an analysis of the frequency 
and cost of doing what must not be done, in addition to 
an analysis of the frequency and cost of AEs associated 
with these practices will be conducted.
definitions
AE is unintentional harm the patient suffers throughout 
the course of the healthcare that is related to the care 
received and not the patient’s underlying illness.30 31
Overuse is the utilisation of tests, procedures or treat-
ments in which the potential harm exceeds the possible 
benefits.1 In this study, continuing to do what must not be 
done (ignoring DNDs) was used as a measure of overuse.
DNDs are practices included on the lists of consen-
sus-based recommendations from governmental institu-
tions or scientific societies to avoid inappropriate overuse, 
and it forms part of the ‘Less is More Medicine’ move-
ment (in Spain, scientific societies call this the ‘Commit-
ment to Quality’).32
Patient safety and overuse
Aim
To identify the frequency and severity of AEs related with 
the frequency of overuse related to DNDs in primary care, 
and the unnecessary cost incurred from such overuse. 
Primary care in Spain includes the practices of general 
practitioners and paediatricians.
Information sources
Computerised databases of primary care medical records 
from national agencies and regional health services, 
electronic clinical history, prescription records, cost infor-
mation of Spanish hospitals and the primary care system, 
and agreements on DNDs for primary care.
Data collection
To determine the overuse related to DNDs, seven DNDs 
from medicine and three from paediatrics, that fulfil the 
criteria of presenting relatively frequently in practice, 
can be reliably identified and can also be the cause of an 
AE, have been chosen based on the prioritisation recom-
mended in a previous study using the Delphi technique 
with 100 healthcare professionals (box 1).33
A two-stage methodology will be used to identify patients 
who suffered avoidable AEs related to DNDs. Figure 2 
illustrates the pathway through the SOBRINA (Grupo de 
Investigación en SOBReutilización INnecesariA; in English, 
"Research Group on Overuse") study. This study assumes 
that there is a higher number of AEs when healthcare 
professionals ignore the DNDs.
In tier 1, the frequency of procedures or treatments 
related to DNDs that persist in the daily practice in 
primary care over the last 3 years will be determined with 
algorithms similar to the indicators of overuse proposed 
by Segal et al.8 These indicators will be applied to deter-
mine the frequency of the DNDs listed in box 1, from 
available electronic information systems (electronic 
history, prescription, etc).
A population database cohort of approximately 
8 294 900 of individuals attended by the public health 
system (data from national agencies and nine Spanish 
regional health services) will be used to determine the 
frequency of procedures or treatments related to DNDs 
during their use of primary care service (figure 3). 
The frequency of DNDs will estimate considering as 
Figure 1 Steps in the design, review and approval of this 
study. 
box 1 do-not-do recommendations selected for analysis 
of the present study
Medicine
1. Prescribe benzodiazepines to treat insomnia, agitation or delirium in 
people older than 65 years.
2. Prescribe non-steroidal anti-inflammatory drugs for patients with 
cardiovascular disease, chronic kidney disease, hypertension, heart 
failure or liver cirrhosis.
3. Recommend taking a dose of 1 g of paracetamol for more than 
3 days.
4. Order antibiotic treatment for acute bronchitis when the patient does 
not suffer from chronic obstructive pulmonary disease, heart failure, 
diabetes or kidney disease, or undergoing active chemotherapy.
5. Prescribe lipid-lowering drugs in patients older than 75 years with-
out previous cardiovascular events.
6. Perform prostate cancer screening in asymptomatic patients.
7. Order image tests in nonspecific lumbago.
Paediatrics
1. Prescribe antibiotics for infants with pharyngitis.
2. Prescribe mucolytic drugs, antitussives or antibiotics for upper res-
piratory infections in infants.
3. Combine treatment between ibuprofen and paracetamol in infants.
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numerator the total number of cases with overuse due 
to ignoring DNDs and denominator the total number of 
patients under a specific condition (see supplementary 
material). These figures will guide the calculation of the 
extra cost that they represent for the entire health system.
In tier 2, we will conduct electronic searches of clin-
ical computer systems to identify patients with avoidable 
AEs (figure 3). Their frequency will be calculated as the 
number of patients with at least one contact or episode 
of event or circumstance that resulted in unintentional 
harm, per 1000 listed patients. The frequencies calculated 
in the first phase (tier 1) will determine the minimum 
number of cases to be included in the study to determine 
potential cases of AE associated with the overuse. In the 
study conducted by Rosenberg et al,9 an assessment of 
seven low-value services revealed that the frequency of 
overuse due to ignoring DNDs ranged from 8% to 85% 
depending on each service. Preliminary data on the 
overuse of services listed in box 1, obtained using the 
algorithms and procedures designed for this study, yield a 
11.3% rate of inadequate prostate cancer screening (one 
case of inadequate decision per nine patients) or 69.4‰ 
of inadequate prescriptions of benzodiazepines to treat 
insomnia, agitation or delirium in elderly persons (one 
case of inadequate prescription per 14 patients). The 
estimated samples in each case ranged from 2110 to 5296, 
depending on the statistical power applied (table 1).
A random sample chosen from clinical histories of 
patients attended over the past 5 years by professionals 
at care centres where medical or nursing attention is 
provided will be used to calculate the frequency of AEs 
for each DND. This period was defined after conducting 
a preliminary trial for extracting data to assure the feasi-
bility of the procedure and to obtain reliable data. The 
care centres participating in this study belong to nine out 
of the 17 currently operating regional health services in 
Spain. In this sample of cases, the potential cases of AEs 
associated with the DNDs will be identified first using 
the trigger tool and reviewing the primary care centre’s 
and hospital’s medical records. Medical charts will be 
retrieved and categorised into the following three groups: 
no AE, AE not likely and AE likely. Once these cases are 
classified, health personnel from the centre where the 
patient was attended will review them in depth to confirm 
whether an AE occurred, will rate its severity and will 
identify its relationship with ignoring DNDs. The APEAS 
(Spanish National Study of Adverse Events in Primary 
Care)34 questionnaire and taxonomy will be used for this. 
This questionnaire was used in the Spanish national study 
to identify frequency, nature, causes and consequences 
Figure 2 Flow diagram for the SOBRINA study. AEs, adverse events. 
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of AEs in primary care. This instrument was designed 
from the questionnaire used in the Harvard Medical 
Practice Study35 36 in its project on patient safety, and it 
was adapted following the experience from the ENEAS 
(Spanish National Study of Adverse Events in Public 
Hospitals)37 study also conducted in Spain to determine 
the frequency of AEs in hospitals. The APEAS question-
naire is complemented by a computer application for 
managing the data called System for Monitoring and 
Controlling AE in Primary Care (the SIVCEA AP 1.0 data-
base).38 The reviewers will complete the form each time 
a case with an AE is identified. They will be classified into 
the following categories: events related to the processes of 
healthcare (including those due to ignoring the DNDs), 
communication gaps, medication, treatment (non-med-
ication) and related to the skills of health professionals. 
The harm severity of each AE will be assessed on a 1–8 
scale. This scale has been adapted from the harm scale 
used previously by Woods et al39 (box 2). The information 
will be introduced into the SIVCEA (Sistema de Información 
para la Vigilancia y Control de Efectos Adversos; in English, 
“Information System for the Surveillance and Control of 
Adverse Effects”) computer application and the forms will 
be safeguarded for an eventual quality review, ensuring 
confidentiality by a blind registration system developed 
box 2 the harm severity scale
1. No harm.
2. Emotional harm.
3. Insignificant harm.
4. Minor temporary harm.
5. Major temporary harm.
6. Minor permanent harm.
7. Major permanent harm.
8. Death.
Figure 3 Overview of methods, data sources, sampling and measures of SOBRINA study. DNDs, do-not-do 
recommendations; AEs, adverse events.
Table 1 Number of clinical histories to be reviewed 
considering different levels of statistical power
Statistical power (%) N* N†
80 2110 3248
85 2400 3696
90 2800 4304
95 3450 5296
*Sample estimates for the inadequate screening of prostate cancer.
†Sample estimates for the inadequate prescriptions of 
benzodiazepines.
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for this study. Reviewers will assess if the AE is related to 
the DNDs using a scale from 0 (no evidence) to 7 (virtu-
ally certain). Scores higher or equal to 4 are deemed to 
indicate a positive relation between the AE and ignoring 
the DND. Reviewers of the forms from each centre will be 
trained to correctly apply this protocol. A degree of agree-
ment is expected between reviewers after conducting this 
training which included example cases. The inter-rater 
agreement, calculated by Kappa coefficient, is expected 
to be greater than 0.80. Moreover, this information will 
permit the estimation of the cost involved in repairing 
the harm associated with the DNDs by summing of the 
direct costs due to the consultation, pharmacy, laboratory 
and imaging activities according to the cases. Figure 3 
illustrates methods, data sources, sample and expected 
outcomes of this study.
Study variables
Frequency of overuse related to DNDs, cost of inappro-
priate overuse, frequency, and severity and cost of AEs 
related to DNDs.
Data analysis
The characteristics of the case of overuse and the trigger 
tool will be described by using absolute frequencies and 
relative frequencies (percentages) for qualitative vari-
ables. The quantitative variables will be expressed using 
means and SDs (in the case of a normal distribution) or 
by using the medians and interquartile ranges (in the case 
of a non-normal distribution). Cumulative rates of AEs 
will be calculated after complete review of the patient’s 
admission, with a 95% CI, and the association between 
the outcome variables (presence/absence of AEs) and 
the remaining variables collected will be measured via a 
bivariate analysis.
For the bivariate analysis, either the χ2 test or Fisher’s 
exact test will be used for the qualitative variables, and 
either Student’s t-test or the Mann-Whitney U Test will be 
used for the quantitative variables (according to whether 
or not they fulfil the normality criteria). Additionally, a 
variance analysis will be conducted to compare various 
means. Statistical analysis of the sample size effect will be 
performed. To control the confusion and/or interaction 
of the explanatory variables related to the severity and 
preventability of AE, a logistic regression will be used. It 
will be conducted using the stepwise forward selection 
method by likelihood ratio. Statistical significance will 
be set at p<0.05 for all the tests used, and the analyses 
will be conducted using Statistical Package for the Social 
Sciences (SPSS) V. 24.0.
Limitations and potential sources of bias
This study aims to identify part of the overuse related to 
safety and sustainability and does not explore the causes 
of overuse related to these DNDs. DNDs may not always 
be clear-cut cases of overuse. The design of this study does 
not permit stablish that doing what must not be done by 
general practitioners or paediatricians is a direct cause 
for AE’s occurrence. Our analysis is based on patients’ 
clinical records; however, the quality of the registered 
information can vary among physicians. The magnitude 
of harm among DNDs could vary from mild to serious, 
thus introducing a detection bias. Lastly, this study does 
not examine patient-level safety risk differences and 
potential regional variations.
Numerators
Overuse in cases determined as stemming from ignoring 
DNDs will be considered (see online supplementary 
material). These frequency data will be divided based on 
age groups (1–3, 4–9, 10–14, 16-44, 45-55, 56–64, 65–75 
and >75 years), gender, professional profile, type of 
health centre (urban or rural) and year. Possible factors 
related with the frequency of overuse due to ignoring 
DNDs (dependent variable) will be identified with a 
logistic regression analysis.
PAtIEnt And PublIC InvolvEMEnt
Patients and or public are not involved.
EthICs
The electronic information available will be reviewed in 
a retrospective manner, taking the case volume and study 
design into account; exemption of informed consent 
from patients has been authorised. Access to information 
will be granted in accordance with the request proce-
dures, treatment and transfer of health data from the 
information services of the health services participating 
in this study. In no case will the project investigators gain 
access to the clinical information of patients.
To ensure confidentiality of the study data, the only 
persons or groups with access to it will be the principal 
investigator (PI) and his/her team of collaborators (from 
the work centre), the promoter or person that the PI 
designates, the ethics committees of the investigation for 
primary care, the relevant health authorities and those 
responsible for the analysis of the said data.
The content of the documents generated throughout 
the study (questionnaire for identifying AEs according to 
the APEAS study) will be safeguarded from unauthorised 
use by individuals external to the investigation and, there-
fore, will be considered strictly confidential and will not 
be revealed to third parties. The PI will ensure anonymity 
of the patients, as well as the protection of their identi-
ties from unauthorised persons. Patients will be identified 
by a code and not by their given name. The PI will be 
responsible for safeguarding the study documentation 
until it is finished.
The project has been drafted in a manner that ensures 
respect for the principles contained in the Declaration of 
Helsinki, the Council of Europe Convention (Oviedo), and 
the UNESCO Universal Declaration. No ethical aspects 
of the investigation contrast the rights of Spanish patients 
contained in Law 41/2002. In this study, regulations and 
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ethical commitments with respect to the analysis of data 
that correspond to minors will be observed carefully. None 
of the participating investigators have commitments with 
industrial or commercial sectors that could interfere with 
the project. Data codification will be based on a masking 
system that respects the confidentiality of the professionals. 
Access to clinical data of the electronic histories will only 
be gained by professionals from the corresponding health 
centres that are authorised for such access, and no identifi-
cation data of the patients or the professional/s involved in 
the care will be codified.
dIssEMInAtIon
First, the documentation of the impact of ignoring DNDs 
in the present study will be doing include in residency 
training programmes for general and community practi-
tioners, paediatricians and nursing training.
Second, the findings will be used to develop a guide 
that demonstrates the impact of ignoring DNDs and 
that proposes changes in the algorithms to assist in clin-
ical decisions-making that can be incorporated into the 
electronic history based on the results obtained. In this 
manner, primary care physicians could rely on assistance 
when prescribing and indicating tests and procedures 
adjusted to the results of this investigation. This guide 
will be available on the website (http://www. nohacer. 
es/). Third, this study will extract results and lessons from 
the study that must be incorporated into Spain’s National 
Strategy on Patient Safety.
Moreover, direct dissemination of the results is planned 
via the project’s website, social networks, mass media, 
scientific societies, as well as in specialised journals and at 
national and international scientific workshops.
dIsCussIon
The literature differentiates between underuse, misuse 
and overuse.40 Until now, most research has focused on 
the first two because they have been easier to address.
Inappropriate overuse is present at all care levels, all 
specialties and all health systems.3 This justifies the recent 
increase in research on this issue,41 despite the fact that 
the frequency data on the frequency of this overuse and 
its impact have not been conclusive due to different meth-
odologies employed to gather them.2
Consensus-based techniques have brought advances in 
producing lists with recommendations about what not to 
do, an approach that has permitted overcoming difficul-
ties when defining the overuse for certain medical proce-
dures and tests. There are fewer studies in primary care, 
but epidemiological studies do exist that include exam-
ples of overuse.27 28
Until now, most published research has been conducted 
in the USA. As such, for example, bronchodilator overuse 
has been estimated to be between 3% and 81%, Pros-
tate-Specific Antigen test overuse from 16% to 80%, 
overuse of antibiotics for upper respiratory tract infections 
from 2% to 89% and overuse of tumour markers from 7% 
to 80%.6 Based on claims by Medicare patients, Segal et al8 
estimated annual extra costs for unnecessary laminecto-
mies of $796 million, $686 million for unnecessary contrast 
abdominal CT scans and $516 million for conducting posi-
tron emission tomography (PET)/TC scans on patients 
with low risk for prostate cancer. In Spain, more than 20% 
of all knee replacements are inappropriate,42 and it has 
been calculated that between 20% and 50% of imaging 
tests could have been avoided; a significant portion of this 
percentage was due to requests by the patients themselves 
or their relatives. The role of the patient in overuse has 
hardly been examined until now.
In several countries, frequency estimations have been 
followed up by information campaigns43–49 targeting clini-
cians and, in some cases, patients, to reduce this overuse. 
Despite their modest results, they seem to point in the 
right direction although greater engagement by all stake-
holders involved is necessary to achieve better results.50
In DNDs, which have spread to all countries,51 the study 
on inappropriate overuse has a new approach based on 
practices for which broad consensus exists that they are 
inadequate or even harmful to patients. These approaches 
are also gradually spreading in all health systems.
The present protocol draws from these considerations 
and exploits the consensus reached in Spain on certain 
DNDs in primary care to establish the frequency of 
overuse of some of these practices that are unnecessary or 
harmful to patients. Furthermore, it also aims to estimate 
their costs for the health system. This is the first study with 
these characteristics to be carried out in Spain, a country 
with a public national health system, where the primary 
care physician (or the paediatrician in case of children) 
is the gatekeeper for the entire system. However, in the 
case of primary care, and as far as we know, inappropriate 
overuse has not been studied systematically, and this 
opens opportunities for new research in other countries.
However, this study also argues that doing what must 
not be done can occasionally harm the patient (causing 
AEs). This aspect has been analysed very little until now,2 
and it is one of the classic problems in patient safety when 
focusing on clearly avoidable AEs.52 This low-value care 
represents an unnecessary risk for the patients that health 
systems must eradicate.
This project contributes to improving patient safety 
in primary care, calling attention to risks that patients 
are subjected to by clinical practices for which ample 
consensus and evidence exist that they should not 
occur. Furthermore, the project provides a measure of 
the economic impact of not following certain DNDs in 
primary care in the Spanish health system.
The project develops a methodology for analysing this 
phenomenon that could then be employed in other coun-
tries to carry out studies on the frequency of the low-value 
care associated with this overuse.
This study quantified the overuse in primary care and 
developed a methodology for measuring the harm caused 
by these ineffective practices that should have been 
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eradicated. This was done to quantifying the magnitude of 
the problem of inappropriate overuse in primary care and 
to understand some of its causes, and to thus lay the basis 
for the development of actions aimed at mitigating this 
problem.
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